Detailed Information on Publication Record
2011
Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy
PAVLÍK, Tomáš, Eva JANOUŠOVÁ, Zdeněk POSPÍŠIL, Jan MUŽÍK, Daniela ŽÁČKOVÁ et. al.Basic information
Original name
Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy
Authors
PAVLÍK, Tomáš (203 Czech Republic, belonging to the institution), Eva JANOUŠOVÁ (203 Czech Republic, belonging to the institution), Zdeněk POSPÍŠIL (203 Czech Republic, belonging to the institution), Jan MUŽÍK (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Hana KLAMOVÁ (203 Czech Republic), Petr CETKOVSKÝ (203 Czech Republic), Marek TRNĚNÝ (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution) and Ladislav DUŠEK (203 Czech Republic, guarantor, belonging to the institution)
Edition
BMC Medical Research Methodology, 2011, 1471-2288
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.668
RIV identification code
RIV/00216224:14110/11:00065561
Organization unit
Faculty of Medicine
UT WoS
000296968400001
Keywords in English
chronic myeloid leukaemia; treatment; statistical methods
Tags
Tags
International impact, Reviewed
Změněno: 31/1/2014 12:43, RNDr. Eva Koriťáková, Ph.D.
Abstract
V originále
The current situation in the treatment of chronic myeloid leukaemia (CML) presents a new challenge for attempts to measure the therapeutic results, as the CML patients can experience multiple leukaemia-free periods during the course of their treatment. Traditional measures of treatment efficacy such as leukaemia-free survival and cumulative incidence are unable to cope with multiple events in time, e.g. disease remissions or progressions, and as such are inappropriate for the efficacy assessment of the recent CML treatment. The results have shown a difference between the estimates of the current cumulative incidence function and the common cumulative incidence of leukaemia-free patients, as well as between the estimates of the current leukaemia-free survival and the common leukaemia-free survival. Regarding the currently available follow-up period, both differences have reached the maximum (12.8% and 20.8%, respectively) at 3 years after the start of follow-up.
Links
NS10621, research and development project |
|